SCHEMBL10016144

SCHEMBL10016144

N[C@H](COc1cncc(-c2ccc3c(c2)/C(=C\c2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 4/20 1.00
DYRK3 O43781 3/20 1.00
ROCK2 O75116 3/20 1.00
PRKD3 O94806 3/20 1.00
MAP4K4 O95819 3/20 1.00
PRKCG P05129 3/20 1.00
PHKG2 P15735 3/20 1.00
CDK2 P24941 3/20 1.00
GSK3A P49840 3/20 1.00
GSK3B P49841 3/20 1.00
PRKX P51817 3/20 1.00
CDK5 Q00535 3/20 1.00
PRKCD Q05655 3/20 1.00
STK3 Q13188 3/20 1.00
PRKG2 Q13237 3/20 1.00
ROCK1 Q13464 3/20 1.00
CAMK2B Q13554 3/20 1.00
CAMK2G Q13555 3/20 1.00
CAMK2D Q13557 3/20 1.00
DYRK1A Q13627 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6849760 1.00 PRKACA (1.00) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6849747 1.00 PRKACA (1.00) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6849753 1.00 PRKACA (1.00) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6849881 0.90 CHEK1 (0.82) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6854515 0.90 CHEK1 (0.82) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6854506 0.90 CHEK1 (0.82) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6849875 0.90 CHEK1 (0.82) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6849880 0.90 CHEK1 (0.82) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL6854511 0.90 CHEK1 (0.82) PRKACADYRK3ROCK2PRKD3MAP4K4
SCHEMBL30035858 0.90 CHEK1 (0.82) PRKACADYRK3ROCK2PRKD3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148089-B2 Alpha-synuclein kinase ELAN PHARMA INTERNATIONAL LIMITED (IE) 2012-04-03 US disclosed
US-8148089-B2 Alpha-synuclein kinase ELAN PHARMA INTERNATIONAL LIMITED (IE) 2012-04-03 US disclosed
US-20110207796-A1 ALPHA-SYNUCLEIN KINASE ELAN PHARMA INTERNATIONAL LIMITED 2011-08-25 US disclosed
US-20110207796-A1 ALPHA-SYNUCLEIN KINASE ELAN PHARMA INTERNATIONAL LIMITED 2011-08-25 US disclosed
US-20100143946-A1 ALPHA-SYNUCLEIN KINASE ELAN PHARMA INTERNATIONAL LIMITED (IE) 2010-06-10 US disclosed
US-20100143946-A1 ALPHA-SYNUCLEIN KINASE ELAN PHARMA INTERNATIONAL LIMITED (IE) 2010-06-10 US disclosed
US-20080300206-A1 Alpha-Synuclein Kinase ELAN PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed
US-20080300206-A1 Alpha-Synuclein Kinase ELAN PHARMACEUTICALS, INC. (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207796-A1 ALPHA-SYNUCLEIN KINASE SNCA, PLK2, LMTK2 PRKACA 140/4885DYRK3 519/4885ROCK2 232/4885
US-20080300206-A1 Alpha-Synuclein Kinase SNCA, PLK2, LMTK2 PRKACA 237/4885DYRK3 339/4885ROCK2 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.